Core Viewpoint - Canopy Growth has experienced a significant decline in value, losing over 99% in the past five years, and is now considered one of the worst-performing stocks in that period [1] Company Overview - Canopy Growth, once a leading Canadian marijuana company, is currently facing challenges and has shifted focus towards cost-cutting and limiting cash burn [6] - The company has a market capitalization of $500 million, which has garnered attention due to recent news regarding the U.S. rescheduling of marijuana [2] Industry Developments - The U.S. government has rescheduled marijuana from a Schedule I to a Schedule III substance, which will facilitate research and reduce tax burdens for multi-state operators [3][4] - This rescheduling is seen as a potential first step towards broader marijuana legalization, although it does not directly benefit Canopy Growth as a Canadian producer [7] Financial Performance - In the most recent quarter ending September 30, Canopy Growth reported an operating loss of CA$16.9 million (approximately $12.2 million), an improvement from CA$45.9 million in the same quarter the previous year [8] - The company's cash burn rate has decreased significantly, with CA$28.3 million used in the last six months compared to CA$105.6 million in the same period a year ago [8]

Core Viewpoint - Tilray Brands, Inc. is at a pivotal moment as it prepares to report its fiscal Q2 2026 results, with a focus on potential profitability amidst regulatory changes in the cannabis industry [1] Group 1: Financial Performance and Expectations - Investors are closely monitoring the upcoming Q2 earnings release for signs of financial improvement, particularly regarding rescheduling, tax relief, and the new Tilray Medical USA subsidiary [2] - Wall Street anticipates a loss of 20 cents per share and quarterly revenue of $210.95 million, with particular attention on U.S. infrastructure investment and potential tax relief during the Q2 call [6] Group 2: Regulatory Changes and Tax Implications - There is optimism among Tilray investors regarding the DEA's expedited process to reclassify cannabis from Schedule I to Schedule III, which could alleviate the Section 280E tax burden [3] - The shift to Schedule III could fundamentally enhance Tilray's profitability by allowing the company to deduct standard business expenses, potentially unlocking millions in annual cash flow [4] Group 3: Strategic Developments - Tilray launched Tilray Medical USA in late December, aiming to transition from a diversified lifestyle brand to a serious medical pharmaceutical player in the U.S. market [5] - The new subsidiary is expected to leverage Tilray's established European medical infrastructure to dominate the physician-led distribution model mandated by Schedule III [5] Group 4: Cash Position and Strategic Decisions - Investors are considering whether Tilray's substantial cash reserves of $265 million will be used for aggressive mergers and acquisitions or if high interest rates and domestic competition will lead to a more cautious approach [7]

Core Viewpoint - The reclassification of marijuana from Schedule I to Schedule III by President Trump on December 18, 2025, represents a significant shift in federal cannabis policy, acknowledging its medical uses and impacting the cannabis industry positively [1][3]. Industry Implications - The executive order allows cannabis companies to deduct more business expenses, which was previously restricted under IRS Code Section 280E, benefiting companies like Green Thumb Industries, Tilray Brands, and Trulieve Cannabis [5][6]. - The reclassification reflects the reality that 40 U.S. states, three territories, and the District of Columbia have legalized medical cannabis, indicating a broader acceptance of marijuana's medical applications [3]. Company Impact - Green Thumb, Tilray, and Trulieve have expressed support for the reclassification, which is expected to provide them with financial advantages and operational flexibility [4][5]. - The exemption from IRS Code Section 280E is particularly critical, as it allows these companies to deduct expenses related to payroll and rent, which were previously non-deductible [6].

Group 1: Economic Measures and Policies - President Trump announced a $1,776 "warrior bonus" for 1.45 million active-duty military personnel, funded by an additional $2.6 billion from tariffs, benefiting approximately 1.28 million active and 174,000 reserve service members [2] - Federal employees will receive an unprecedented two additional days off for Christmas, creating a five-day holiday period, with the government closing on December 24 and 26 [3] - Trump signed an executive order to relax marijuana regulations, moving it from Schedule I to Schedule III, which will facilitate more clinical research and FDA reviews [4][6] Group 2: Housing and Drug Pricing Initiatives - Trump promised to unveil a housing reform plan to address the housing affordability crisis, while claiming inflation has "stopped" [7] - Major pharmaceutical companies, including Merck and GSK, agreed to voluntarily lower drug prices in exchange for tariff exemptions and regulatory relief, with Novartis committing to invest $23 billion in the U.S. over five years [7] Group 3: Political Context and Challenges - Trump's policy announcements come amid declining approval ratings, with Ipsos polling showing his support at 39%, and challenges related to rising living costs and the upcoming 2026 midterm elections [1][9] - The unemployment rate rose to 4.6% in November, the highest since October 2021, with approximately 7.83 million unemployed, indicating economic pressures that could impact the Republican party's control in Congress [8][9]

Group 1 - President Trump announced a $1,776 "warrior bonus" for 1.45 million active-duty military personnel, attributing the funding to additional revenue from tariffs [2] - The bonus is part of a broader strategy to address declining approval ratings and economic uncertainty, with Ipsos polling showing his approval at 39% [1][7] - Trump also signed an executive order granting federal employees two additional days off for Christmas, creating a five-day holiday period [3] Group 2 - An executive order was signed to reclassify marijuana from a Schedule I to Schedule III substance, which will facilitate more clinical research and FDA reviews [4][5] - The Trump administration announced a housing reform plan and a drug price discount agreement with major pharmaceutical companies, including Merck and Novartis [6] - The drug price agreement aims to lower costs for government insurance programs and includes commitments from companies to invest billions in the U.S. [6] Group 3 - Economic pressures are mounting, with the unemployment rate rising to 4.6%, the highest since October 2021, and a significant number of Americans feeling financial strain [7][8] - Polls indicate that only 33% of Americans approve of Trump's economic policies, marking the lowest approval rating during his second term [8] - Critics, including Senator Mark Warner and economist Paul Krugman, suggest that Trump's recent announcements are attempts to divert attention from economic challenges [9]

Core Viewpoint - The signing of the executive order by President Trump on December 18 aims to reclassify cannabis from a Schedule I controlled substance to a Schedule III controlled substance, which will facilitate medical research and exploration of cannabis's benefits and potential harms [1][3]. Group 1: Regulatory Changes - The reclassification will lower the barriers for medical research on cannabis, allowing it to be recognized for certain medical uses [3]. - Schedule III substances are defined as having a moderate to low risk of physical and psychological dependence, which includes some common medications like Tylenol with codeine [3]. - The executive order mandates the U.S. Attorney General to expedite the process of relaxing federal restrictions on cannabis, although no specific timeline is provided [3]. Group 2: Political and Industry Support - The cannabis industry has engaged in extensive lobbying efforts to encourage the Trump administration to ease cannabis regulations, receiving significant support from various political factions [4][5]. - The "American Rights and Reform Political Action Committee," backed by the cannabis industry, has made substantial donations to Trump's campaign, including $1 million to the "Make America Great Again" super PAC [5]. - Key executives from major cannabis companies have met with Trump to discuss the potential for job creation and the need for regulatory changes [6]. Group 3: Public Perception and Criticism - Critics warn that lowering the classification of cannabis may send a misleading message about its dangers, potentially normalizing its use among the public, especially youth [9]. - The cannabis industry is viewed as a multi-billion dollar sector, with increasing accessibility and potential for growth, despite ongoing federal restrictions [10].

全球财经媒体昨夜今晨共同关注的头条新闻主要有： 美国核心通胀意外放缓至逾四年新低 经济学家怀疑数据因停摆而失真 美国11月核心通胀同比增幅创2021年初以来最低水平，通胀形势意外出现改善；美国联邦政府先前的停 摆加大了此份报告的解读难度。 美国劳工统计局周四公布的数据显示，11月剔除波动性较大的食品和能源的核心消费者价格指数 （CPI）同比上升2.6%，11月整体CPI同比涨幅为2.7%。 1、美国核心通胀意外放缓至逾四年新低 经济学家怀疑数据因停摆而失真 2、特朗普下令放宽大麻管制 行业获重大监管利好 3、微软、谷歌等24家公司加入美国政府的人工智能"创世使命" 4、美光科技涨超10%：人工智能存储需求飙升，公司直言产品已全面售罄 5、卢特尼克面临民主党议员审查 数据中心项目关联引发争议 6、特朗普称赞沃勒和鲍曼 称将在未来几周内公布美联储主席人选 美国联邦政府此次停摆的持续时间创出纪录，使得劳工统计局无法收集到大量10月的价格数据，不仅局 限了该机构确定11月整体通胀环比变化的能力，也使一些经济学家指出，同比数据可能也受到了影响。 特朗普下令放宽大麻管制 行业获重大监管利好 美国总统唐纳德·特朗普周四签署 ...

Core Viewpoint - President Donald Trump signed an executive order to reclassify marijuana from Schedule I to Schedule III, significantly impacting the cannabis industry and leading to a surge in US cannabis stocks [1] Group 1: Executive Order Impact - The executive order directs federal agencies to change the classification of marijuana, which could lead to increased research and development opportunities within the cannabis sector [1] - This reclassification is expected to reduce regulatory burdens on cannabis companies, potentially enhancing their operational capabilities and market access [1] Group 2: Market Reaction - Following the announcement, US cannabis stocks experienced a sharp increase, indicating strong investor optimism regarding the future of the cannabis market [1] - The market response reflects a growing acceptance of cannabis and its potential for commercialization, which may attract more investment into the sector [1]

Core Viewpoint - The company is strategically positioning itself to capitalize on the growing opportunities in the industrial hemp market in the United States by establishing subsidiaries and conducting market research [1] Group 1: Company Initiatives - The company has set up two subsidiaries in the U.S., E10 Labs and S10 Labs, to leverage the rapid development of the industrial hemp sector [1] - E10 Labs has been granted the legal qualification to engage in processing and manufacturing activities locally, as well as to sell products in the U.S. and other legally compliant countries [1] - The company has launched a series of heat-not-burn products through E10 Labs, indicating its commitment to innovation in the industrial hemp space [1] Group 2: Market Research and Development - The company emphasizes the importance of comprehensive scientific market research to support production and R&D efforts, aiming to provide forward-looking market information [1] - The subsidiaries are focused on meeting the international market demand for industrial hemp extracts and end products [1] - S10 Labs primarily serves as a provider of hardware for industrial hemp vaporizers, showcasing the company's diversified approach within the industry [1]

Core Viewpoint - U.S. cannabis stocks experienced a significant after-hours rally, driven by reports that former President Trump plans to sign an executive order to reclassify cannabis [1] Group 1: Stock Performance - Tilray Brands saw an increase of over 4% in after-hours trading [1] - Canopy Growth rose nearly 7% during the same period [1] - Aurora Cannabis experienced a rise of over 2% [1]